Free Trial
NASDAQ:BXRX

Baudax Bio (BXRX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.02
$0.02
50-Day Range
$0.02
$0.03
52-Week Range
$0.01
$3.47
Volume
310,800 shs
Average Volume
281,029 shs
Market Capitalization
$1.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BXRX stock logo

About Baudax Bio Stock (NASDAQ:BXRX)

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.

BXRX Stock News Headlines

Baudax Bio Announces Corporate Update
“Generational Bull Run” Incoming
LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.
Why Is Baudax Bio (BXRX) Stock Up 75% Today?
“Generational Bull Run” Incoming
LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.
Why Is Baudax Bio (BXRX) Stock Up 130% Today?
Baudax Bio (BXRX) Gets a Hold from Noble Financial
Noble Financial Sticks to Their Hold Rating for Baudax Bio (BXRX)
Baudax Improves on Q1 Results
See More Headlines
Receive BXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Baudax Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/16/2023
Today
7/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BXRX
Employees
9
Year Founded
N/A

Profitability

Net Income
$-58,790,000.00
Pretax Margin
-18,950.64%

Debt

Sales & Book Value

Annual Sales
$1.27 million
Book Value
($14.93) per share

Miscellaneous

Free Float
52,408,000
Market Cap
$1.14 million
Optionable
Not Optionable
Beta
1.57
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Geraldine A. Henwood Ph.D. (Age 72)
    President, CEO & Director
    Comp: $633.25k
  • Mike Choi
    Vice President of Financial Planning & Analysis
  • Ms. Natalie McAndrew (Age 53)
    Consultant & Principle Accounting Officer
  • Dr. Chan Kim Yong Ph.D. (Age 50)
    Chief Scientific Officer & Director

BXRX Stock Analysis - Frequently Asked Questions

How were Baudax Bio's earnings last quarter?

Baudax Bio, Inc. (NASDAQ:BXRX) posted its earnings results on Wednesday, August, 16th. The company reported ($1.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.04) by $0.55.

When did Baudax Bio's stock split?

Baudax Bio's stock reverse split on the morning of Wednesday, November 30th 2022. The 1-40 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Baudax Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Baudax Bio investors own include Sorrento Therapeutics (SRNE), Coty (COTY), NIO (NIO), VBI Vaccines (VBIV), ADMA Biologics (ADMA), Energy Transfer (ET) and Remark (MARK).

This page (NASDAQ:BXRX) was last updated on 7/27/2024 by MarketBeat.com Staff

From Our Partners